Engineered immune cells take aim at Hard-to-Treat lupus
NCT ID NCT06935474
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This early-stage study tests a new treatment called C-CAR168 for people with lupus nephritis (kidney inflammation from lupus) that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy harmful cells driving the disease. The study will enroll 24 adults and focus on safety and finding the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AbelZeta, Inc.
Rockville, Maryland, 20850, United States
Conditions
Explore the condition pages connected to this study.